1-(Furan-2-yl)azepine | 940959-24-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 杂芳族化合物
• 英文名称: 1-(Furan-2-yl)azepine
• CAS: 940959-24-0
• 化学式: C₁₀H₉NO
• 分子量: 159.188
• InChiKey: QPEQCQGZFJAGOL-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.8
• 重原子数：
  12
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  16.4
• 氢给体数：
  0
• 氢受体数：
  2

文献信息

• Process for producing N-(hetero)aryl-substituted nitrogen-containing heteroaryl compound
  申请人：Ishikawa Yuji

  公开号：US20070135633A1

  公开（公告）日：2007-06-14

  A process for producing an N-(hetero)aryl-substituted nitrogen-containing heteroaryl compound, the process comprising: reacting a heteroaryl compound having an NH group as a ring-constituting component with a (hetero)aryl compound having a leaving group in the presence of a heterogeneous-system platinum group metal catalyst, a ligand and a base.

  一种生产N-(杂)芳基取代的含氮杂芳基化合物的方法，包括在异质铂族金属催化剂、配体和碱的存在下，将具有NH基团作为环构成组分的杂芳基化合物与具有离去基团的(杂)芳基化合物反应。
• Process for producing N-(Hetero)Aryl-substituted nitrogen-containing heteroaryl compound
  申请人：FUJIFILM FINECHEMICALS CO., LTD.

  公开号：EP1795529A2

  公开（公告）日：2007-06-13

  A process for producing an N-(hetero)aryl-substituted nitrogen-containing heteroaryl compound, the process comprising: reacting a heteroaryl compound having an NH group as a ring-constituting component with a (hetero)aryl compound having a leaving group in the presence of a heterogeneous-system platinum group metal catalyst, a ligand and a base.

  一种生产 N-（杂）芳基取代的含氮杂芳基化合物的工艺，该工艺包括：在异质系铂族金属催化剂、配体和碱存在下，使具有 NH 基作为成环组分的杂芳基化合物与具有离去基团的（杂）芳基化合物反应。
• SUBSTITUTED AZEPINE DERIVATIVES AS SEROTONIN RECEPTOR MODULATORS
  申请人：Athersys, Inc.

  公开号：EP1778243A2

  公开（公告）日：2007-05-02
• US7834183B2
  申请人：——

  公开号：US7834183B2

  公开（公告）日：2010-11-16
• [EN] SUBSTITUTED AZEPINE DERIVATIVES AS SEROTONIN RECEPTOR MODULATORS<br/>[FR] DERIVES D'AZEPINE SUBSTITUES UTILISES COMME MODULATEURS DES RECEPTEURS DE LA SEROTONINE
  申请人：ATHERSYS INC

  公开号：WO2006004931A2

  公开（公告）日：2006-01-12

  The present invention generally relates to a series of compounds, to pharmaceutical compositions containing the compounds, and to use of the compounds and compositions as therapeutic agents. More specifically, compounds of the present invention are hexahydroazepinoindole and octahydroazepinoindole compounds. These compounds are serotonin receptor (5-HT) ligands and are useful for treating diseases, disorders, and conditions wherein modulation of the activity of serotonin receptors (5-HT) is desired (e.g. anxiety, depression and obesity).